BacterOMIC

System ready
for hospital
and central laboratory use

Responding to one of the most important challenges of modern medicine

Comprehensive
susceptibility
testing

Rapid access to effective antibiotic therapy (AST)

Fully automatic
system

Shortens and simplifies laboratory procedures

Comprehensive
susceptibility
testing

Rapid access to effective antibiotic therapy (AST)

Fully automatic
system

Shortens and simplifies laboratory procedures

System ready
for hospital
and central laboratory use

Responding to one of the most important challenges of modern medicine

Obtaining international patent protection for the inventions “Microfluidic Chip and Incubation Segment”.

Obtaining international patent protection for the invention “Method for rapid detection of bacterial growth”

The project has received funding from the European Union’s HORIZON 2020
research and innovation funding programme under Agreement No 881101.

BACTEROMIC

Learn about our system

BacterOMIC is a diagnostic system designed to address one of the most important challenges in modern medicine – multidrug resistance.

BacterOMIC consists of an Analyzer, Filling Device, and Panels for drug susceptibility assessment. As an automated system, it significantly simplifies and shortens laboratory procedures used in the evaluation of drug susceptibility of microorganisms.

The system allows phenotypic evaluation of the efficacy of 25 antibiotics used to treat respiratory, blood, urinary tract, or skin infections, among others.

Owing to the determination and expertise of a team of biotechnologists, engineers and software developers, and an innovative approach to the problem of modern diagnostics, a device has been created with considerable market potential and offering to revolutionize antibiotic treatment.

CE-IVD

The Bacteromic system has the CE IVD marking enabling marketing authorization in the European Union.

ISO 13485

Bacteromic Sp. z o. o. has a certificate of compliance of the quality management system with the ISO 13485:2016-04 standard (Medical devices – Quality management systems – Requirements for legal purposes) granted by CeCert Sp. z o. o.

BACTEROMIC Sp. z o.o.

The BacterOMIC system has been developed by the Scope Fluidics Group, which develops innovative medical diagnostic devices as part of its special purpose vehicle Bacteromic sp. z o.o.

Meet the Management Board of Bacteromic sp. z o.o.

piotr garstecki

Co-founder of Scope Fluidics. Chemistry professor and manager. He conducted scientific and technical projects in Poland and the United States, specializing in soft matter physics and microfluidic techniques. Passionate about the development of the organization and building value by creating technologies that solve important problems in health care.

Piotr Garstecki

President of the Management Board

piotr garstecki

Co-founder of Scope Fluidics. Manager. He gained experience in technology companies, research institutes and pharmaceutical companies. In his professional work, he coordinated a number of implementation processes. An enthusiast of risk management and solving difficult problems. At Scope Fluidics, he is responsible for clinical trials, intellectual property, production and registration processes.

Marcin Izydorzak

Member of the Board

piotr garstecki

A manager with many years of experience in managing capital groups, implementing M&A transactions and cooperation with the capital market, including raising capital from international institutions. At Scope Fluidics, he is responsible for the financial department, M&A transactions and investor relations.

Szymon Ruta

Member of the Board

Find out more about Scope Fluidics S.A.

BacterOMIC

BacterOMIC
A unique diagnostic solution

For doctors and patients

Ensuring that clinicians have access to complete, i.e., practical, information on antibiotic susceptibility of pathogenic bacteria
Accelerating access to precision antibiotic therapy
Minimizing the risk of complications in treatment of bacterial infections
Minimizing hospitalization time and treatment costs

Strengths

640 incubation chambers per Panel
One panel for Gram-positive and Gram-negative bacteria to simplify work and reduce confusion
Analyzer’s capacity suitable for medium and large laboratories
System equipped with simple interface software and expert system to interpret results according to current EUCAST recommendations
Easy-to-use (manual procedure limited to pipetting the inoculum and closing Panel)
Fully compatible with working standards in microbiology
Automated to simplify the process and minimize errors

Procedure for Use

Tests carried out in specialist diagnostic centres have confirmed the functionality of the BacterOMIC system in effectively identifying drug susceptibility of bacteria causing a range of infections. As emphasized by doctors and experts at the World Health Organisation (WHO), antibiotic resistance is one of the most serious problems in modern medicine.

Procedure for Use

Isolated
bacterial strain

Monoculture
bacterial suspension

Transfer of suspension
to cartridge

Closure of cap

Placement of cartridges
in rack

Placement of
rack in
automatic filling unit

Single filling of up
to 10 cartridges

Transfer of filled
cartridges to Analyzer

Fully automated analysis
of up to 60 samples

BacterOMIC Analyzer

WIDTH 82,8 cm

HEIGHT 87,5 cm

DEPTH 59,5 cm

WEIGHT 79,5 kg

POWER SUPPLY 230 VAC 50 Hz 10 A

BacterOMIC Filling Device

WIDTH 32 cm

HEIGHT40 cm

DEPTH60 cm

WEIGHT41 kg

POWER SUPPLY230 VAC 50 Hz 8 A

BacterOMIC Diagnostic Panel

*pre-IVDR

Effective antibiotic therapies

The BacterOMIC system enables single identification of the efficacy of a range of 31 antibiotics used in treatment of infections of the respiratory system, blood, urinary tract, or skin, among others. It is a rapid and accurate assessment of drug susceptibility of Gram-positive and Gram-negative bacteria in a single diagnostic panel.

BacterOMIC Panel UNI

Recipients

MICROBIOLOGY
LABORATORIES

CENTRAL
LABORATORIES

HOSPITALS

Technology

640 independent bacterial cultures in each single test

BacterOMIC is the world’s unique solution with the ultimate goal of being able to test as many as 640 bacterial culture conditions in a single test. This will translate into the capacity to compose a single test for the vast majority of clinically used antibiotics.

Unique combination of technologies used in the BacterOMIC system provides for a variety of potential applications

Did you know…?

The WHO has announced that antimicrobial resistance is one of the top 10 global public health threats facing humanity
According to the latest data, the number of deaths related to antibiotic resistance in bacteria in 2019 was estimated at 4.95 million
According to OECD data, antimicrobial resistance results in more than 700 million additional hospitalization days per year
One of the main factors contributing to the development of antibiotic resistance is inappropriate selection and overuse of antibiotics